1. High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients.
- Author
-
Lewis K.L., Jakobsen L.H., Villa D., Bobillo S., Ekstroem Smedby K., Savage K.J., Eyre T.A., Cwynarski K., Caporn P.L., Zyl J.V., Klanova M., Trneny M., Puckrin R., Stewart D.A., Bishton M.J., Fox C.P., Tun A.M., Thanarajasingam G., Djebbari F., Joffe E., Eloranta S., Harrysson S., Sehn L.H., Maliske S.M., Poonsombudlert K., Guo X., Hapgood G., Manos K., Hawkes E., Khwaja J., Minson A., Dickinson M., Ovlisen A.K., Gregory G.P., Gilbertson M., Streit I.T., Scott H.W., Ku M., de Mel S., Yong K.Y., Xin L., Mokoonlall M., Talaulikar D., McVilly N.L., Johnston A., Brunner M.J., Pophali P.A., Maurer M.J., El-Galaly T.C., Cheah C.Y., Lewis K.L., Jakobsen L.H., Villa D., Bobillo S., Ekstroem Smedby K., Savage K.J., Eyre T.A., Cwynarski K., Caporn P.L., Zyl J.V., Klanova M., Trneny M., Puckrin R., Stewart D.A., Bishton M.J., Fox C.P., Tun A.M., Thanarajasingam G., Djebbari F., Joffe E., Eloranta S., Harrysson S., Sehn L.H., Maliske S.M., Poonsombudlert K., Guo X., Hapgood G., Manos K., Hawkes E., Khwaja J., Minson A., Dickinson M., Ovlisen A.K., Gregory G.P., Gilbertson M., Streit I.T., Scott H.W., Ku M., de Mel S., Yong K.Y., Xin L., Mokoonlall M., Talaulikar D., McVilly N.L., Johnston A., Brunner M.J., Pophali P.A., Maurer M.J., El-Galaly T.C., and Cheah C.Y.
- Abstract
[Formula presented] Introduction Central nervous system relapse (secondary central nervous system lymphoma -SCNS) is an uncommon but devastating complication of aggressive B-cell lymphoma. Patients (Pts) with CNS-IPI 4-6 are at greatest risk (10.2% at 2 years). Intravenous high-dose methotrexate (HD-MTX) is widely used to mitigate SCNS risk but data supporting this practice are limited. Methods We performed a multicentre, retrospective study at 21 sites in Australia, Asia, North America and Europe. Chart or registry review was performed for consecutively diagnosed pts with diffuse large B-cell lymphoma (DLBCL) and CNS-IPI 4-6, high grade B-cell lymphoma (HGBL) with rearrangements of MYC+BCL2 and/or BCL6 and primary breast/testicular DLBCL irrespective of CNS-IPI. Pts were diagnosed between 2000-2020, 18-80 years at diagnosis, and treated with curative intent anti-CD20 based chemo-immunotherapy. Pts with CNS involvement at diagnosis were excluded. HD-MTX was defined as at least one cycle of intravenous MTX at any dose. Time to SCNS was calculated from date of diagnosis (all-pts), and from the end of frontline systemic lymphoma therapy, defined as 6x21 days from diagnosis (complete response (CR-pts)), until SCNS, systemic relapse, death, or censoring, whichever came first. Cumulative risk of SCNS was computed using the Aalen-Johansen estimator treating death and systemic relapses as competing events. Adjusted cumulative risks were obtained by using an inverse probability of treatment weighting approach. The average treatment effect was computed as the difference in adjusted 5-year risk of SCNS. Results - 2300 and 1455 pts were included in the all-pts and CR-pts analyses, respectively. Baseline demographics and details of therapy are summarised in Table 1. Except for a predominance of males, pts <=60 years and pts with ECOG 0-1 in the HD-MTX vs no HD-MTX groups, the demographics and treatments were well balanced. At a median follow up of 5.9 years (range 0.0-19.1) and
- Published
- 2021